 |
市場調查報告書
商品編碼
1672804
全球膽管癌市場按治療類型、通路和地區分類Bile Duct Cancer Market, By Treatment Type , By Distribution Channel, By Geography |
||||||
2025 年全球膽管癌市場規模估計為 40.3 億美元，預計到 2032 年將達到 71.8 億美元，2025 年至 2032 年的複合年成長率為 8.6%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025 年市場規模 | 40.3億美元 |
| 效能資料 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期：2025-2032年複合年成長率： | 8.60% | 2032 年價值預測 | 71.8億美元 |
膽管癌，也稱為膽道癌，是一種在膽管中發生的罕見癌症。膽管是連接肝臟和膽囊與小腸的管道。當膽管內壁細胞變得異常且不受控制地生長形成腫瘤時，就會發生膽管癌。導致膽管癌的主要危險因子包括原發性硬化性膽管炎 (PSC)、發炎性腸道疾病、肝功能不全和某些膽管先天性異常。症狀包括黃疸、搔癢、腹痛、體重減輕和大便蒼白。診斷通常涉及超音波、 電腦斷層掃描或MRI掃描等影像檢查以及切片檢查。治療方案取決於癌症的階段，可能包括手術、放射線治療、化療和標靶治療。但由於膽管癌早期發現困難且腫瘤生長緩慢，存活率較低、預後較差。
市場動態：
全球膽管癌市場的成長主要受到原發性膽管癌 (PSC) 和肝吸蟲感染等風險因素日益流行的推動。根據美國疾病管制與預防中心 (CDC) 的數據，PSC 影響了美國約 3 萬人。對膽管癌缺乏了解和延遲診斷也導致其在晚期才被診斷出來，從而推動了市場的成長。此外，增加標靶藥物的研發資金以改善膽管癌的治療效果也可能為市場相關人員提供有利可圖的機會。然而，疾病意識低下和手術程序複雜可能會阻礙市場成長。
本研究的主要特點
- 本報告對全球膽管癌市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和復合年成長率。
- 它還揭示了各個領域的潛在商機並說明了該市場的引人注目的投資提案矩陣。
- 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
- 它根據公司亮點、產品系列、關鍵亮點、績效和策略等參數，介紹了全球膽管癌市場的主要企業概況。
- 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 全球膽管癌市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員將透過用於分析全球膽管癌市場的各種策略矩陣更輕鬆地做出決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章市場動態、法規與趨勢分析
- 市場動態
- 驅動程式
- 限制因素
- 機會
- 影響分析
- 市場趨勢
- 主要進展
- 監管情景
- 收購和合作場景
- 資金籌措和投資
- PEST分析
- 波特的分析
第 4 章。全球膽管癌市場：COVID-19 大流行的影響
- 整體影響
- 政府舉措
- COVID-19 市場影響
第 5 章 全球膽管癌市場按治療類型分類（2020-2032 年）
- 化療
- 標靶治療
- 免疫療法
- 其他
6. 全球膽管癌市場依通路分類（2020-2032 年）
- 院內藥房
- 零售藥局
- 網路藥局
7. 全球膽管癌市場按地區分類（2020-2032 年）
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第8章 競爭格局
- 公司簡介
- F. Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Merck &Co., Inc.
- Novartis AG
- Celgene Corporation
- Johnson &Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Fresenius Kabi AG
- Mylan NV
- ConMed Corporation
- Boston Scientific Corporation
- Taiho Pharmaceutical Co., Ltd.
- Incyte Corporation
第9章分析師建議
- 命運之輪
- 分析師觀點
- Coherent Opportunity Map（COM）
第10章參考文獻與調查方法
- 參考
- 調查方法
Global Bile Duct Cancer Market is estimated to be valued at USD 4.03 Bn in 2025 and is expected to reach USD 7.18 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.03 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.60% | 2032 Value Projection: | USD 7.18 Bn |
Bile duct cancer, also known as cholangiocarcinoma, is a rare type of cancer that forms in the bile duct. The bile duct is a tube that connects the liver and gallbladder to the small intestine. Bile duct cancer occurs when the cells that line the bile ducts become abnormal and grow uncontrollably, forming a tumor. Key risk factors for developing bile duct cancer include primary sclerosing cholangitis (PSC), an inflammatory bowel disease, liver flukes, and certain congenital abnormalities of the bile ducts. Symptoms may include jaundice, itching, abdominal pain, weight loss, and pale stools. Diagnosis usually involves imaging tests such as ultrasound, CT scan, and MRI scans, as well as biopsy. Treatment options depend on the stage of cancer and include surgery, radiation therapy, chemotherapy, and targeted therapy. However, bile duct cancer has a poor prognosis with low survival rates due to difficulties in early detection and slow growth nature of the tumors.
Market Dynamics:
Global bile duct cancer market growth is primarily driven by increasing prevalence of risk factors such as PSC and liver flukes infections. According to the Center for Disease Control and Prevention (CDC), PSC affects around 30,000 people in the U.S. Insufficient understanding and delays in diagnosing bile duct cancer also contribute to late-stage diagnosis, thus, driving the market growth. Moreover, rising research funding towards targeted drug development for improving the bile duct cancer treatment outcomes can offer lucrative opportunities for market players. However, low disease awareness and complexity in surgical procedures can hamper the market growth.
Key Features of the Study:
- This report provides in-depth analysis of the global bile duct cancer market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bile duct cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Eli Lilly, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, and Bristol-Myers Squibb Company
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global bile duct cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bile duct cancer market
Detailed Segmentation-
- By Treatment Type
- Chemotherapy
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- (Pembrolizumab (Phase 3))
Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- Celgene Corporation
- Johnson & Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Fresenius Kabi AG
- Mylan N.V.
- ConMed Corporation
- Boston Scientific Corporation
- Taiho Pharmaceutical Co., Ltd.
- Incyte Corporation
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global Bile Duct Cancer Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global Bile Duct Cancer Market, By Treatment Type, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gemcitabine
- Cisplatin
- Oxaliplatin
- Capecitabine
- 5 fluorouracil (5-FU)
- Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- (Pembrolizumab (Phase 3)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Bile Duct Cancer Market, By Distribution Channel, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Bile Duct Cancer Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Celgene Corporation
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Fresenius Kabi AG
- Mylan N.V.
- ConMed Corporation
- Boston Scientific Corporation
- Taiho Pharmaceutical Co., Ltd.
- Incyte Corporation
- F. Hoffmann-La Roche Ltd
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
